Our top pick for
Aileron Therapeutics, Inc is a biotechnology business based in the US. Aileron Therapeutics shares (ALRN) are listed on the NASDAQ and all prices are listed in US Dollars. Aileron Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of USD$46 million.
|Latest market close||USD$1|
|52-week range||USD$0.25 - USD$2.47|
|50-day moving average||USD$1.0513|
|200-day moving average||USD$1.213|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.605|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-18.70%|
|1 month (2020-12-17)||-0.99%|
|3 months (2020-10-15)||-48.45%|
|6 months (2020-07-15)||4.17%|
|1 year (2020-01-15)||22.03%|
|2 years (2019-01-15)||-12.28%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Gross profit TTM||USD$-17,663,000|
|Return on assets TTM||-52.62%|
|Return on equity TTM||-132.65%|
|Market capitalisation||USD$46 million|
TTM: trailing 12 months
There are currently 1.2 million Aileron Therapeutics shares held short by investors – that's known as Aileron Therapeutics's "short interest". This figure is 6.6% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Aileron Therapeutics shares can be evaluated.
Aileron Therapeutics's "short interest ratio" (SIR) is the quantity of Aileron Therapeutics shares currently shorted divided by the average quantity of Aileron Therapeutics shares traded daily (recently around 738291.875). Aileron Therapeutics's SIR currently stands at 1.6. In other words for every 100,000 Aileron Therapeutics shares traded daily on the market, roughly 1600 shares are currently held short.
However Aileron Therapeutics's short interest can also be evaluated against the total number of Aileron Therapeutics shares, or, against the total number of tradable Aileron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aileron Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aileron Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0345% of the tradable shares (for every 100,000 tradable Aileron Therapeutics shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aileron Therapeutics.
Find out more about how you can short Aileron Therapeutics stock.
We're not expecting Aileron Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aileron Therapeutics's shares have ranged in value from as little as $0.25 up to $2.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aileron Therapeutics's is 3.1398. This would suggest that Aileron Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.